ByPeter Schmid, MD,Hwei-Chung Wang,Filipa Lynce,Yeon Hee Park,Cynthia X. Ma, MD, PhD,Kyung Hae Jung,Shin-Cheh Chen,Ming-Feng Hou,Catherine Prady,Ling-Ming Tseng,Jamil Asselah,Piotr J. Wysocki,Simon Lord,Purnima Rao-Melacini,Ross Stewart,Karola Warzyszyńska,Petra Vuković,Seock-Ah Im Dato-DXd plus durvalumab demonstrated robust antitumor activity as first-line treatment for advanced/metastatic triple-negative breast cancer in the phase 1b/2 BEGONIA study, with manageable safety.